Obesity and overweight in relation to adenocarcinoma of the esophagus

Cancer Prevention and Management through Exercise and Weight Control

Volumn , Issue , 2016, Pages 269-286

  Hoyo, Cathrine ^a   Gammon, Marilie D ^b  

^a DUKE CANCER INSTITUTE   (United States)

^b Breast Cancer Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123746217     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (100)

1. Parkin DM. Bray F. Ferlay J. Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer, 2001; 94(2):153-156.
2. Parkin DM. Bray FI. Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer, 2001; 37 Suppl 8:S4-66.
3. Vizcaino AP. Moreno V. Lambert R. Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer, 2002; 99:860-868.
4. Devesa SS. Blot WJ. Fraumeni JF. Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the U.S. 1998; Cancer, 1998; 83(10):2049-2053.
5. Mokdad AH. Serdula MK. Dietz WH. Bowman BA. Marks JS. Koplan JP. The spread of obesity epidemic in the U.S. 1991-1998. JAMA, 1999; 282:1519-1522.
6. Mokdad AH. Ford ES. Bowman BA. Dietz WH. Vinicor F. Bales VS. Marks JS. Prevalence of obesity, diabetes and obesity-related health risk factors. JAMA, 2003; 289:76-79.
7. National Center for Health Statistics. http://www.fedstats.gov/key_stats/NCHSkey.html.
8. Sturm R. Increases in clinically severe obesity in the U.S., 1986-2000. Arch Intern Med, 2003; 16:2146-2148.
9. Bray GA. Commentary on classics in obesity. Life insurance and overweight. Obesity Res, 1995; 3:97-99.
10. De Michele M. Panico S. Iannuzzi A. Celentano E. Ciardullo AV. Galasso R. Sacchetti L. Zarrilli F. Bond MG. Rubba P. Association of obesity and central fat distribution with carotid artery wall thickening in middle-aged women. Stroke, 2002; 33(12):2923-2928.
11. Calle EE. Rodriguez C. Walker-Thurmond K. Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med, 2003; 348(17):1625-1638.
12. Munoz N. Day NE. Esophageal cancer. In: Fraumeni JF. Jr. Ed. Cancer Epidemiology and Prevention. New York. Oxford University Press, 1996; 681-706.
13. Gammon MD. Schoenberg JB. Ahsan H. Risch HA. Vaughan TL. Chow WH. Rotterdam H. et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst, 1997; 89(17):1277-1284.
14. Chow WH. Blaser MJ. Blot WJ. Gammon MD. Vaughan TL. Risch HA. Perez-Perez GI. Schoenberg JB. Stanford JL. Rotterdam H. West AB. Fraumeni JF. Jr. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res, 1998; 58:588-90.
15. Chow WH. Blot WJ. Vaughan TL. Risch HA. Gammon MD. Stanford JL. et al. Body mass index and risk of adenocarcinoma of the esophagus and gastric cardia. J Natl Cancer Inst, 1998; 90:150-155.
16. Wu AH. Wan P. Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (U.S.). Cancer Causes Control, 2001; 12:721-732.
17. Lagergren J. Bergstrom R. Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med, 1999; 130:883-890.
18. Tretli S. Robsahm TE. Height, weight and cancer of the esophagus and stomach: a follow-up study in Norway. Eur J Cancer Prev, 1999; 8:115-122.
19. Farrow DC. Vaughan TL. Sweeney C. Gammon MD. Chow WH. Risch HA. Stanford JL. Hansten PD. Mayne ST. Schoenberg JB. Rotterdam H. Ahsan H. West AB. Dubrow R. Fraumeni JF. Jr. Blot WJ. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control, 2000; 11(3):231-238.
20. Vaughan TL. Esophagus. In: Franco EL. Rohan TE. Eds. Cancer Precursors - Epidemiology, Detection, and Prevention, 2002. Springer-Verlag. New York; p. 96-116.
21. Ji BT. Chow WH. Yang G. McLaughlin JK. Gao RN. Zheng W. Shu XO. et al. Body mass index and risk of cancers of the gastric cardia and distal stomach in Shanghai, China. Cancer Epidemiol Biomarkers Prev, 1997; 6:481-485.
22. Knudson AG. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Nat Acad Sci USA, 1971; 68:820-823.
23. Kuczmarski RJ. Flegal KM. Criteria for definition of overweight in transition: background and recommendations for the U.S. Am J Clin Nutr, 2000; 72:1074-1081.
24. Bray GA. Bouchard C. James WPT. Definition and proposed current classification of obesity. In: Bray GA. Bouchard C. James WPT. Eds. Handbook of Obesity. New York: Marcel Dekker, 1998; 31-40.
25. Kabat GC. Ng SK. Wynder EL. Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control, 1993; 4:123-132.
26. Brown LM. Silverman DT. Pottern LM. Schoenberg JB. Greenberg RS. Swanson GM. et al. Adenocarcinoma of the esophagus and esophagogastric junction in white men in the U.S.: alcohol, tobacco, and socioeconomic factors. Cancer Causes Control, 1994; 5:333-340.
27. Vaughan TL. Davis S. Kristal A. Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma vs. squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev, 1995; 4:85-92.
28. Zhang ZF. Kurtz RC. Sun M. Karpeh M. Jr. Yu GP et al. Adenocarcinomas of the esophagus and gastric cardia: medical conditions, tobacco, alcohol, and socioeconomic factors. Cancer Epidemiol Biomarkers Prev, 1996; 5:761-768.
29. Incarbone R. Bonavina L. Szachnowicz S. Saino G. Peracchia A. Dis Esophagus, 2000; 13:275-278.
30. Chen H. Ward MH. Graubard BI. Heineman EF. Markin RM. Potischman NA. et al. Dietary patterns and adenocarcinoma of the esophagus and distal stomach. Am J Clin Nutr, 2002; 75:137-144.
31. Cheng KK. Sharp L. McKinney PA. Logan RFA. Chilvers CED. Cook-Mozaffari P. et al. A casecontrol study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer, 2000; 83:127-132.
32. Chak A. Lee T. Kinnard MF. Brock W. Faulx A. Willis J. Cooper GS. Sivak MV. Goddard KAB. Familial aggregation of Barrett's esophagus, esophageal adenocarcinoma and esophagogastric junction adenocarcinoma in Caucasian adults. Gut, 2002; 51:323-328.
33. Bollschweiler E. Wolfgarten E. Nowroth T. Rosendahl U. Monig SP. Holscher AH. Vitamin intake and risk of esophageal cancer in Germany. J Cancer Res Clin Oncol, 2002; 128:575-580.
34. Caygill CPJ, Johnston DA, Lopez M, Johnsto BJ, Watson A, Reed PI, Hill M. Lifestyle factors and Barrett's esophagus. Am J Gatsroenerol, 2002; 97:1328-1331.
35. Moe GL. Kristal AR. Levine DS. Vaughan TL. Reid BJ. Waist-to-hip ratio and dietary and serum selenium are associated with DNA content flow cytometry in Barrett's esophagus. Nutr Cancer, 2000; 36:7-13.
36. Gerson LB. Shetler K. Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroentorology, 2002; 123:636-639.
37. Vaughan TL. Kristal AR. Blount PL. Levine DS. Galipeau PC. Prevo LJ. Sanchez CA. Rabinovitch PS. Reid BJ. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev, 2002; 11:745-752.
38. Farrow DC. Vaughan TL. Sweeney C. Gammon MD. Chow WH. Risch HA. Stanford JL. Hansten PD. Mayne ST. Schoenberg JB. Rotterdam H. Ahsan H. West AB. Dubrow R. Fraumeni JF. Jr. Blot WJ. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control, 2000; 11:231-238.
39. Avidan B. Sonnenberg A. Schnell TG. Chejfec G. Metz A. Sontag SJ. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol, 2002; 97(8):1930-1936.
40. Bjorntorp P. Hormonal control of regional fat distribution. Hum reprod. 1997; 12 Suppl 1:21-25.
41. Murray L. Johnston B. Lane A. Harvey I. Donovan J. Nair P. Harvey R. Relationship between body mass and gastroesophageal reflux symptoms: the Bristol Helicobacter Project. Int J Epidemiol, 2003; 32:645-650.
42. Nilsson M. Johnston R. Ye W. Hveem K. Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA, 2003; 290:66-72.
43. Mathus-Vliegen EM. Tygat GN. Gastroesophageal reflux in obese subjects: influence of overweight, weight, weight loss and chronic gastric balloon distension. Scand J Gastroenterol, 2002; 37:1246-1252.
44. Ruhl CE. Everhat JE. Overweight, but not high fat intake, incraeses risk of gastroesophageal reflux disease hospitalization: the NHANES I Epidemiologic Follow-Up Study. First National Health and Nutrition Examination Survey. Ann Epidemiol, 1999; 9:424-435.
45. Locke GR. III. Talley NJ. Fett SL. Zinsmeister AR. Melton LJ. III. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med, 1999; 106:642-649.
46. Fraser-Moddie CA, Norton B. Gornall C. Magnago S. Weale AR. Holmes GK. Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. Scand J Gatsroenterol, 1999; 34:337-340.
47. Kjellin A. Ramel S. Rossner S. Thor K. Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol, 1996; 31:1047-1051.
48. Lagergren J. Bergstrom R. Nyren O. No relation between body mass index and gastroesophageal reflux symptoms in a Swedish population based study. Gut, 2000; 47:26-29.
49. Wilson LJ. Ma W. Hirschowitz BI. Association of obesity with hiatal hernia and esophagitis. Am J Gastroenterol, 1999; 94:2840-2844.
50. Mayne ST. Navarro SA. Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr, 2002; 132(11 Suppl):3467S-3470S
51. Bowers SP. Mattar SG. Smith CD. Waring JP. Hunter JG. Clinical and histologic follow-up after antireflux surgery for Barrett's esophagus. J Gastrointestinal Surg, 2002; 6:532-8.
52. La Veccia C. Negri E. Lagiou P. Trichopolos D. Oesophageal adenocarcinoma: a paradigm of mechanical carcinogenesis. Int J Cancer, 2002; 102:269-270.
53. Kopelman PG. Finer N. Reply: is obesity a disease? Int J Obesity Relat Metab Disorders, 2001; 25:1405-1406.
54. Bouchard C. Bray GA. Hubbard VS. Basic and clinical aspects of regional fat distribution. Am J Clin Nutr, 1990; 52:946-950.
55. Mercer CD. Wren SF. DaCosta LR. Beck IT. Lower esophageal sphincter pressure and gastroesophageal pressure gradients in excessively obese patients. J Med, 1987;18(3-4):135-146.
56. Mercer CD. Rue C. Hanelin L. Hill LD. Effect of obesity on esophageal transit. Am J Surg, 1985; 149:177-181.
57. Preston-Martin S. Pike MC. Ross RK. Jones PA. Henderson BE. Increased cell division as a cause of human cancer. Cancer Res, 1990; 50:7415-7421.
58. Pollak M. Insulin-like growth factors and prostate cancer. Epidemiologic Rev, 2001; 23:59-66.
59. Yu H. Mistry J. Nicar MJ. Khosravi MJ. Diamandis A. van Doorn J. Juul A. Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. J Clin Lab Anal, 1999; 13:166-172.
60. Yi HK. Hwang PH. Yang DH. Kang CW. Lee DY. Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur J Cancer, 2001; 37:2257-2263.
61. Hankinson SE. Willett WC. Colditz GA. Hunter DJ. Michaud DS. Deroo B. Rosner B. Speizer FE. Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 1998; 351(9113):1393-1396.
62. Bruning PF. Van Doorn J. Bonfrer JM. Van Noord PA. Korse CM. Linders TC. Hart AA. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable premenopausal breast cancer. Int J Cancer, 1995; 62(3):266-270.
63. Toniolo P. Bruning PF. Akhmedkhanov A. Bonfrer JM. Koenig KL. Lukanova A. Shore RE. Zeleniuch-Jacquotte A. Serum insulin-like growth factor-I and breast cancer. Int J Cancer, 2000; 88:828-832.
64. Bohlke K. Cramer DW. Trichopoulos D. Mantzoros CS. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology, 1998; 9(5):570-573.
65. Chan JM. Stampfer MJ. Giovannucci E. Gann PH. Ma J. Wilkinson P. Hennekens CH. Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science, 1998; 279:563-566.
66. Stattin P. Stenman UH. Riboli E. Hallmans G. Kaaks R. Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection. J Clin Endocrinol Metab, 2001; 86:5745-5748.
67. Mantzoros CS. Tzonou A. Signorello LB. Stampfer M. Trichopoulos D. Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer, 1997; 76:1115-1118.
68. Harman SM. Metter EJ. Blackman MR. Landis PK. Carter HB. Baltimore Longitudinal Study on Aging. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab, 2000; 85:4258-4265.
69. Wolk A. Mantzoros CS. Andersson SO. Bergstrom R. Signorello LB. Lagiou P. Adami HO. Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst, 1998; 90:911-915.
70. Djavan B. Susani M. Bursa B. Basharkhah A. Simak R. Marberger M. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol, 1999; 5:139-142.
71. Ma J. Pollak MN. Giovannucci E. Chan JM. Tao Y. Hennekens CH. Stampfer MJ. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3 [see comment]. J Natl Cancer Inst, 1999; 91:620-625.
72. Giovannucci E. Pollak MN. Platz EA. Willett WC. Stampfer MJ. Majeed N. Colditz GA. Speizer FE. Hankinson SE. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev, 2000; 9:345-349.
73. Kaaks R. Toniolo P Akhmedkhanov A. Lukanova A. Biessy C. Dechaud H. Rinaldi S. Zeleniuch-Jacquotte A. Shore RE. Riboli E. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst, 2000; 92:1592-1600.
74. Reeve JG. Morgan J. Schwander J. Bleehen NM. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res, 1993; 53:4680-4685.
75. Manousos O. Souglakos J. Bosetti C. Tzonou A. Chatzidakis V. Trichopoulos D. Adami HO. Mantzoros C. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer, 1999; 83:15-17.
76. Okosun IS. Anochie LK. Chandra KM. Racial/ethnic differences in prehypertension in American adults: Population and relative attributable risk of abdominal adiposity. J Hum Hypertension, 2004;18:849-855.
77. Dandona P. Mohanty P. Ghanim H. Aljada A. Browne R. Hamouda W. Prabhala A. Afzal A. Garg R. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab, 2001; 86:355-362.
78. Wiencke JK. DNA adduct burden and tobacco carcinogenesis. Oncogene, 2002; 21(48):7376-7391.
79. Urakawa H. Katsuki A. Sumida Y. Gabazza EC. Murashima S. Morioka K. Maruyama N. Kitagawa N. Tanaka T. Hori Y. Nakatani K. Yano Y. Adachi Y. Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab, 2003; 88(10):4673-4676.
80. Dandona P. Aljada A. Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol, 2004; 25(1):4-7.
81. Tang D. Cho S. Rundle A. Chen S. Phillips D. Zhou J. Hsu Y. Schnabel F. Estabrook A. Perera FP Polymorphisms in the DNA repair enzyme XPD are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer. Breast Cancer Res Treatment, 2002; 75:159-166.
82. Duell EJ. Millikan RC. Pittman GS. Winkel S. Lunn RM. Tse CK. Eaton A. Mohrenweiser HW. Newman B. Bell DA. Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Biomarkers Prev, 2001; 10(3):217-222.
83. van Gils CH. Bostick RM. Stern MC. Taylor JA. Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer risk: an example of polymorphisms in the XRCC1 gene. Cancer Epidemiol Biomarkers Prev, 2002; 11:1279-1284.
84. Rybicki BA. Conti DV. Moreira A. Cicek M. Casey G. Witte JS. DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 2004; 13:23-29.
85. Chen S. Tang D. Xue K. Xu L. Ma G. Hsu Y. Cho SS. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis, 2000; 23(8):1321-1325.
86. David-Beabes GL. Lunn RM. London SJ. No association between the XPD (Lys751G1n) polymorphismor the XRCC3 (Thr241Met) polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev, 2001; 10(8):911-912.
87. Winsey SL. Haldar NA. Marsh HP. Bunce M. Marshall SE. Harris AL. Wojnarowska F. Welsh KI. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res, 2000; 60(20):5612-5616.
88. Sturgis EM. Castillo EJ. Li L. Zheng R. Eicher SA. Clayman GL. Strom SS. Spitz MR. Wei Q. Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis, 1999; 20:2125-129.
89. Wang M. Abbruzzese JL. Friess H. Hittelman WN. Evans DB. Abbruzzese MC. Chiao P. Li D. DNA adducts in human pancreatic tissues and their potential role in carcinogenesis. Cancer Res, 1998; 58(1):38-41.
90. DeWeese TL. Hruszkewycz AM. Marnett LJ. Oxidative stress in chemoprevention trials. Urology, 2001; 57(4 Suppl 1):137-140.
91. Fleshner NE. Kucuk O. Antioxidant dietary supplements: rationale and current status as chemopreventive agents for prostate cancer. Urology, 2001; 57(4 Suppl 1):90-94.
92. Nieman DC. Nehlsen-Cannarella SI. Henson DA. Butterworth DE. Fagoaga OR. Warren BJ. Rainwater MK. Immune response to obesity and moderate weight loss. Int J Obesity Relat Metabolic Disorders: J Int Assoc Study Obesity, 1996; 20(4):353-360.
93. Plotkin BJ. Paulson D. Chelich A. Jurak D. Cole J. Kasimos J. Burdick JR. Casteel N. Immune responsiveness in a rat model for type II diabetes (Zucker rat, fa/fa): susceptibility to Candida albicans infection and leucocyte function. J Med Microbioly, 1996; 44:277-283.
94. Moriguchi S. Kato M. Sakai K. Yamamoto S. Shimizu E. Exercise training restores decreased cellular immune functions in obese Zucker rats. J Appl Physiol, 1998; 84:311-317.
95. Oka M. Attwood SE. Kaul B. Smyrk TC. DeMeester TR. Immunosuppression in patients with Barrett's esophagus. Surgery, 1992; 112(1):11-17.
96. Letsch A. Keilholz U. Schadendorf D. Assfalg G. Asemissen AM. Thiel E. Scheibenbogen C. Functional CCR9 expression is associated with small intestinal metastasis. J Invest Dermatol, 2004;122:685-690.
97. Murakami T. Cardones AR. Hwang ST. Chemokine receptors and melanoma metastasis. J Dermatol Sci, 2004; 36:71-78.
98. Ghobrial IM. Bone ND. Stenson MJ. Novak A. Hedin KE. Kay NE. Ansell SM. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Mayo Clinic Proc, 2004; 79:318-325.
99. Van Damme J, Struyf S, Opdenakker G. Chemokine-protease interaction in cancer. Semin Cancer Biol, 2004; 14:201-208.
100. Zabel Zella D. Barabitskaja O. Casareto L. Romerio F. Secchiero P. Reitz MS., Jr. Gallo RC. Weichold FF. Recombinant INF-alpha 2b increases the expression of apoptosis CD95 and chemokine receptors CCR1 and CCR3 in momocytoid cells. J Immunol, 1999; 163:3169-3175.